IL17A and rheumatoid arthritis: Thus, we speculate that ST2825-mediated MyD88 inhibition could prevent the adverse effects of IL-17 signalling on RA PBMC; in parallel, we propose that future studies should be focused on identifying ST2825-mediated effects on Th17 cells from RA patients.